

Autism

Biomedical Complementary Treatment Approaches

Robert L. Hendren, DO

KEYWORDS

- Autism • Complementary and alternative treatment • Integrative treatment
- Biomedical treatment

KEY POINTS

- Families commonly seek alternative and complementary biomedical treatments with children with autistic spectrum disorders (ASD).
- Although there are many biomedical CAM treatments in use, there is little evidence from well-conducted randomized controlled trials (RCT) to support claims of efficacy or safety.
- A potential rationale for biomedical CAM treatments in autism is their potential beneficial effect on epigenetic processes, which are increasingly shown to play a role in the gene-environment interactions underlying the development of ASD.
- Three agents with a rationale for use with ASD, at least one RCT showing efficacy, and safety data include melatonin, omega-3, and micronutrients.
- Additional agents with promise include N-acetylcysteine and methylcobalamin (methyl B12), digestive enzymes, and memantine.
- Care providers should be prepared to thoughtfully discuss biomedical CAM treatments with families to help them make informed decisions regarding the best options for their child and for their family's values.

INTRODUCTION

This article provides an overview of the biomedical subgroup of complementary and alternative medicine (CAM) treatments for autism spectrum disorders (ASD). These biomedical treatments include a variety of natural products, such as vitamins and minerals, melatonin, and digestive enzymes; procedures, such as neurofeedback and

Disclosures: Within the past year, the author has received research grants from Forest Pharmaceuticals, Inc; Bristol Meyer Squibb; Otsuka America Pharmaceutical, Inc; Curemark; BioMarin; Autism Speaks; the Vitamin D Council; and NIMH. The author is on an advisory board for BioMarin, Forest, Lilly, and the Autism Speaks Treatment Advisory Board. The author is not on any speakers bureaus.

Child and Adolescent Psychiatry, Department of Psychiatry, University of California, San Francisco, 401 Parnassus Avenue, LP-360, San Francisco, CA 94143-0984, USA

E-mail address: Robert.Hendren@ucsf.edu

Child Adolesc Psychiatric Clin N Am ■ (2013) ■■■

<http://dx.doi.org/10.1016/j.chc.2013.03.002>

childpsych.theclinics.com

1056-4993/13/\$ – see front matter © 2013 Elsevier Inc. All rights reserved.

49 chelation; some conventional medications that are being examined for new applica-
50 tions in treating autism, such as antifungals and memantine; diets; and nutraceuticals.
51 Nutraceutical agents are foods or food products that purportedly provide health and
52 medical benefits, including the prevention and treatment of disease. Biomedical
53 CAM treatments are integrative in nature, and most of them can be used in combina-
54 tion with conventional treatments for autism.

55 The authors do not review the large number of CAM treatments that are less
56 biomedical in nature, such as mind/body approaches; body-based practices, such
57 as physical manipulation; or alternative medical systems, such as Ayurvedic or tradi-
58 tional Chinese medicine, despite the promising suggestive findings for some of these
59 treatments.


60 This article begins with a description of the evolving understanding of the cause of
61 ASD and how the recent shift in the etiologic paradigm is leading to increasing assess-
62 ment of treatment targets and the use of biomedical and CAM treatments. Many of the
63 potential biomedical CAM treatments are listed, and the ones with the most evidence
64 or most focus of public interest are reviewed briefly, along with a discussion of the
65 research models necessary to identify which children will be most likely to respond
66 to which treatments. Finally, a model is discussed for working with families who
67 have a member with an ASD when considering biomedical/CAM treatments. When
68 the term *autism* is used alone, it refers to *autistic disorder* as defined in the *Diagnostic*
69 *and Statistical Manual of Mental Disorders* (Fourth Edition). When *ASD* is used, it refers
70 to the spectrum of autism disorders from mild to severe.

71 Complementary and alternative treatments are commonly used. Although 12% of
72 children and adolescents in the United States use CAM treatments,¹ up to 70% of chil-
73 dren with ASD are reported to use some form of biologic treatment (either CAM or
74 conventional),² and an even higher percentage (up to 74%) of children with recently
75 diagnosed autism use only CAM and not conventional psychopharmacologic agents.³
76 The main reasons for families' choice of CAM were related to concerns with the safety
77 and side effects of prescribed medications.³ Families are reported to expect their
78 primary care physicians to have knowledge about CAM treatments,⁴ yet many physi-
79 cians do not feel knowledgeable about them.

81 ***Cause of Autism and the Biomedical Concept***

82 The cause of autism is widely accepted to be strongly genetic in origin, but the
83 increasing prevalence and recent studies of the genetics of autism^{5,6} suggest that the
84 cause of autism is also related to gene-by-environment interactions expressed through
85 or manifest in epigenetic processes. Epigenetics refers to the reversible regulation
86 of various genomic functions, independent of DNA sequence, mediated principally
87 through DNA methylation, chromatin sequence, and RNA-mediated gene expression.⁷
88 The related endophenotypes (measurable components along the epigenetic pathway
89 between the genotype and the distal symptom, personal characteristic, or phenotype)
90 are simple biologic aspects of a disease that can be observed in unaffected relatives
91 with a similar endophenotype at a higher rate than in the general population⁸ and that
92 are potentially reversible through nutrition, social factors, behavioral interventions,
93 and drugs.⁹ Executive and frontal lobe functions shared by family members may be
94 examples.

95 In autism, this process of gene-environment interaction and the resulting endo-
96 phenotypes might be viewed schematically as a model in which the layers of the
97 earth represent the expression of the genotype into various types of the phenotype
98 (**Fig. 1**). The surface of the earth represents the personal expression and symptoms
99 we see (phenotype), and the core of the earth represents the genes of that person



117 **Fig. 1.** Surface (phenotype) to core (genotype) model of endophenotype.

118
119
120 (genotype). In between is the complex and interactive layering of developmental
121 processes that represent the endophenotype. Interventions targeting the surface
122 level 4 might include behavioral interventions, such as applied behavior analysis
123 and the external provision of structure. Levels 3 to 4 can be targeted with occupa-
124 tional therapy, physical therapy, speech and language therapy, and cognitive behav-
125 ior therapy; levels 3 to 2 with pharmacotherapy; deeper into levels 3 and 2 with
126 biomedical and CAM therapies; and level 1 with treatments that result in gene
127 modification.

128 This middle earth of levels 2 and 3 is the target of biomedical therapy in autism and
129 other neurodevelopmental disorders and entails various active biochemical or physi-
130 ologic processes such as the following:

- 131
132
133
134
135
136
137
138
- Immune abnormalities/inflammation¹⁰
 - Oxidative stress¹¹
 - Disturbed methylation¹¹
 - Mitochondrial dysfunction¹²
 - Free fatty acid metabolism¹³
 - Excitatory/inhibitory imbalance¹⁴
 - Hormonal effects¹⁵

139 Such abnormal epigenetic processes are not found in all people with ASD or may
140 be active only during particular periods of time (Fig. 2). Therefore, treatment
141 research should recruit subjects for trials based on the state of their previously vali-
142 dated endophenotypic biomarkers¹⁶ to know if an intervention is targeting an active
143 biomedical process in the subject at that time. For instance, identifying an inflamma-
144 tory process through a biomarker such as a cytokine abnormality could be entry
145 criteria to a study of an antiinflammatory agent for the treatment of autism. Other
146 biomarkers of the active epigenetic process might be such measures as glutathione
147 (GSH) metabolites, glutamate and γ -aminobutyric acid, magnetic resonance imag-
148 ing, genomic arrays, and others based on the current gene-by-environment interac-
149 tion altering the epigenetic process¹⁷ and are discussed further in studies presented
150 later in this article.

151 Various biochemical and physiologic processes operate at levels 2 and 3; various
 152 biomedical CAM therapies can target these processes, including CAM therapies
 153 described by Levy and Hyman¹⁸⁻²⁰:

- 154 • Neurotransmitter production or release (dimethylglycine, vitamin B6 with magne-
 155 sium, vitamin C, omega-3 fatty acids, St. John's wort)
- 156 • Food sensitivities and gastrointestinal function (gluten-free casein-free [GFCF]
 157 diets, secretin, digestive enzymes, famotidine [Pepcid], antibiotics)
- 158 • Putative immune mechanism or modulators (antifungals, intravenous immuno-
 159 globulin [IVIG], vitamin A/cod liver oil)
- 160 • Potential heavy metal toxin removal (chelation)
- 161 • Methylation (methylcobalamin, folinic acid)
- 162 • Nonbiologic (craniosacral manipulation, transcranial magnetic stimulation,
 163 acupuncture)

165 **Biomedical Treatments**

166 Biomedical treatments include both conventional treatments, such as psychopharma-
 167 cological agents, and less studied and less medically accepted treatments, such as
 168 nutraceuticals, as well as other types of treatments, including devices like transcranial
 169 magnetic stimulation.

170 Risperidone and aripiprazole are the only medications that the Food and Drug
 171 Administration (FDA) has given approval for marketing for the indication of *irritability*
 172 *associated with autism*. Irritability is not a core symptom of autism, and no drug has
 173




Fig. 2. Endophenotype stress cycle.

the FDA's marketing approval for the indication of autism itself or for any core symptom of autism.

Conventional pharmacologic treatments for symptoms associated with ASD include stimulants, antidepressants, antipsychotics, anticonvulsants, and anxiolytics. Each of these agents has been examined for autism-related symptoms in published studies, and comprehensive critical reviews of this literature are available in 2 excellent recent articles.^{21,22}

Pharmacologic agents that are not traditionally considered as treatments of ASD or associated symptoms but that have one or more published studies for the treatment of symptoms associated with autism include propranolol,²³ amantadine,²⁴ D-cycloserine,²⁵ cholinesterase inhibitors,²⁶ nicotinic agonist,²⁷ memantine,²⁸ naltrexone,²⁹ and buspirone.³⁰

The list of potential biomedical CAM treatments is long and most have inadequate evidence to judge potential efficacy. See **Box 1** for a list of most of the biomedical CAM treatments of ASD. Two comprehensive reviews of those treatments with reasonable efficacy data have been recently published.^{31,32}

For this short article, the biomedical CAM treatments that have the most published evidence, that have generated the greatest interest or controversy, and/or that nonetheless have significant promise for treating autism or autism-associated symptoms are briefly discussed. These treatments include melatonin, omega-3, injectable methylcobalamin (methyl B12), N-acetylcysteine (NAC), memantine, pancreatic digestive enzymes, micronutrients, immune therapies, and chelation.

Melatonin

Melatonin is an endogenous neurohormone released by the pineal gland in response to decreasing levels of light. It causes drowsiness and sets the body's sleep clock. ASD is associated with a high frequency of sleep problems, and melatonin is increasingly used to help children with ASD fall asleep.^{33,34} Rossignol and Frye³⁵ published a review and meta-analysis of 35 studies. They described reports of abnormalities in melatonin levels in patients with ASD (9 studies: 7 low, 2 high, 4 circadian); significant correlations between melatonin levels and ASD symptoms (4 studies); and gene abnormalities associated with decreased melatonin production (5 studies). Of 18 treatment studies of melatonin, there were 5 randomized controlled trials (RCTs) involving a total of 61 patients treated with nightly doses of 2 to 10 mg. These RCTs showed positive effects on sleep in that sleep duration was increased (44 minutes, Effect Size [ES] = 0.93) and sleep onset latency was decreased (39 minutes, ES = 1.28), but nighttime awakenings were unchanged. The duration of the studies varied between 4 weeks and 4 years. One study suggested a loss of benefit at 4 weeks, whereas the study of 4 years reported continued benefits. The side effects were minimal to none.

Melatonin is one of the best-studied biomedical CAM treatments of ASD. Although small sample sizes, variability in sleep assessments, and lack of follow-up limit the value of these studies in supporting its use, treatment with melatonin has a clear physiologic rationale; and it is sensible, easy, cheap, and safe.

Omega-3 Fatty Acids

Omega-3 long-chain fatty acid supplementation is reasonable to consider because omega-3 fatty acids are essential to brain function and development.³⁶ They are a critical component of neuronal membranes, they are essential for their optimal functioning, and they serve as substrates for the production of the eicosanoids, such as prostaglandins, which are necessary for cell communication and immune regulation. The two omega-3 fatty acids of primary interest are eicosapentaenoic acid (EPA) and

Box 1**Potential biomedical CAM treatments of ASD**

Pioglitazone hydrochloride (Actos)
 Acupuncture
 Animal-assisted therapy
 Antibiotics
 Antifungals (fluconazole [Diflucan], nystatin)
 Antiviral (valacyclovir hydrochloride [Valtrex])
 Amino acids
 Auditory integration therapy (music therapy)
 Chelation
 Chiropractic
 Cholestyramine
 Coenzyme Q10
 Craniosacral therapy
 Curcumin
 Cyproheptadine
 Dehydroepiandrosterone
 Digestive enzymes
 Dimethylglycine, trimethylglycine
 Fatty acids (omega-3)
 5-hydroxytryptophan
 Folic/folinic acid
 GSH
 GFCF diet
 Food-allergy treatment
 Hyperbaric oxygen treatment
 Iron
 Infliximab (Remicade)
 Immune therapies
 IVIG
 L-carnosine
 Magnesium
 Melatonin
 Methylcobalamin (methyl B12)
 N-acetylcysteine
 Naltrexone
 Neurofeedback
 Oxalate (low) diet
 Oxytocin

304 Pyridoxal phosphate
 305 Probiotics
 306 Ribose and dehydroepiandrosterone
 307 S-adenosyl-methionine
 308 Secretin
 309 Sensory integration therapy
 310 Specific carbohydrate diet
 311 St. John's wort
 312 Steroids
 313 Transfer factor
 314 Vitamin A
 315 Vitamin B3
 316 Vitamin B6 with magnesium
 317 Vitamin C
 318 Zinc

325 docosahexaenoic acid (DHA). Based on data from other disorders, they might be expected to improve mood, attention, and activity level as well as, conceivably, actual symptoms of autism. Low levels of omega-3 fatty acids have been reported in children with ASD.^{37–39}

329 There have been 4 open trials^{35,38,40} and 2 double-blind, placebo-controlled, randomized pilot trials in children with ASD.^{41,42} Amminger and colleagues⁴² randomized 13 children (aged 5–17 years) to EPA 840 mg and DHA 700 mg daily ($n = 7$) or placebo ($n = 6$) for 6 weeks. There were no significant differences between groups on the Aberrant Behavior Checklist, possibly because of the small sample and insufficient power; but omega-3 seemed nominally superior to placebo for stereotypy (Cohen's $d = 0.72$), hyperactivity ($d = 0.71$), and inappropriate speech ($d = 0.39$). In a study by Bent and colleagues,⁴³ 27 children (aged 3–8 years) with ASD were randomly assigned to 12 weeks of omega-3 fatty acids (1.3 g/d) or an identical placebo. Hyperactivity seemed to improve more in the omega-3 group than in the placebo group, although not with statistical significance (2.7 ± 4.8 vs 0.3 ± 7.2 , $P = .40$). Correlations were found between decreases in the levels of 5 different fatty acids and decreases in hyperactivity, with milder changes in other behaviors. There were no differences in side effects. A larger Internet-based study of omega-3 fatty acid supplementation is currently underway.

344 With only 2 small placebo-controlled RCTs totaling 38 children, and all 4 open studies without statistically significant effects (possibly a power issue), the evidence is small for omega-3 supplementation in ASD. This effect of omega-3 supplementation on hyperactive behavior might mirror recent suggestions of a modest,⁴⁴ though debatable,⁴⁵ effect of omega-3 fatty acids in treating attention-deficit hyperactivity disorder (ADHD). Despite the weak evidence and the modest effect, it has a rationale for its use; and it is sensible, easy, inexpensive, and safe.

352 **Methylcobalamin (Methyl B12)**

353 Methyl B12 is a vital cofactor for the regeneration of methionine from homocysteine, by providing methyl groups for metabolic pathways involving transmethylation and

transsulfuration. Reduced activity in the transsulfuration pathway can lead to reduced levels of cysteine and GSH, which are crucial antioxidants responsible for minimizing macromolecular damage produced by oxidative stress.

James and colleagues¹¹ showed that many children with ASD exhibit low levels of GSH and a decreased GSH/GSSG redox ratio. In an open-label trial in 40 children with autism, administration of methyl B12 for 1 month resulted in a significant increase in plasma GSH concentrations, although behavioral assessments were not done in this study.¹¹ Improvements were noted in social relatedness, language, and behavior problems.

In a recent study, 30 patients completed a 12-week, double-blind RCT of subcutaneously injected methyl B12 at a dosage of 64.5 mcg/kg every 3 days; 22 patients completed the 6-month extension study.⁴⁶ The supplement was well tolerated. No statistically significant differences in behavior tests or in GSH status were identified between active and placebo groups. However, 9 (30%) patients demonstrated clinically significant improvement on the Clinical Global Impression–Improvement Scale and at least 2 behavioral and language measures. Improvements in social interaction and language were most consistently reported. Notably, this subgroup of responders exhibited significantly increased concentrations of GSH and GSH/GSSG compared with the nonresponders. This study is the only published RCT, but a new RCT from the same group will be completed in early 2013. Additional research is needed to delineate a subgroup of responders and ascertain a biomarker of response to methyl B12.

Methyl B12 is typically administered at dosages of 64.5 to 75.0 mcg/kg with subcutaneous injections every 2 to 3 days. There are no studies in ASD of oral or nasal methyl B12, which do not maintain consistently high levels and are thought to be less effective. Subcutaneous injectable methyl B12 does seem to be safe. Although initial studies are promising for a subgroup of children with ASD, and subcutaneous injectable methyl B12 supplementation seems to be safe and well tolerated, additional study is needed to determine whether this will become a recommended treatment of ASD. However, despite reasonable cost, with repeated frequent injections, this treatment is not easy to use.

NAC

NAC is a glutamatergic modulator and an antioxidant. There is one published report of a 12-week, double-blind, randomized, placebo-controlled study of NAC in children with autism.⁴⁷ Patients (31 boys, 2 girls; aged 3–10 years) were randomized, and NAC was initiated at 900 mg daily for 4 weeks, then 900 mg twice daily for 4 weeks, and 900 mg 3 times daily for 4 weeks. Compared with placebo, oral NAC resulted in significant improvements on the Aberrant Behavior Checklist (ABC) irritability subscale ($P < .001$; $d = 0.96$) and induced limited side effects. The results are promising, especially because the supplement is well tolerated; but this study will need to be replicated before recommendations can be offered.

Memantine

There are biochemical studies suggesting that aberrant functioning of the N-methyl D-aspartic acid (NMDA) receptor and/or altered glutamate metabolism may play a role in autism. Memantine is a moderate-affinity antagonist of the NMDA glutamate receptor and is hypothesized to potentially modulate learning by blocking excessive glutamate effects that can include neuroinflammatory activity. Its capacity to block glutamate neurotoxicity and neuroinflammatory activity and to stimulate synapse formation makes it an interesting candidate for treating autism. An open-label case series reported significant improvement in language and socialization in children with

autism.²⁸ Memantine is well tolerated in children, and a multisite RCT is currently underway. This treatment could be considered off-label use of a conventional medication approved for the treatment of Alzheimer disorder rather than as a CAM treatment.

Pancreatic Digestive Enzymes

Enzyme deficiencies in children with autism result in a reduced ability to digest protein, which affects the availability of amino acids essential for brain function. There is increasing evidence for a gut-brain connection associated with ASD, at least in some cases.⁴⁸ This finding suggests a possible benefit from a comprehensive digestive enzyme supplement with meals to aid digestion of all proteins and peptides, especially for those children with ASD who have gastrointestinal disturbance.

Probiotics (consisting of microorganisms thought to improve digestive health by repopulating the gastrointestinal tract with favorable flora) have also been proposed to improve digestion and gut-brain activity in children with ASD. Some proponents suggest these agents may also help remove toxins and improve immune function.

A double-blind placebo-controlled trial of digestive enzyme supplementation using a 6-month crossover design in 43 children with ASD (aged 3–8 years) did not show any clinically significant improvement of ASD symptoms.⁴⁹ A possible effect on improvement in the variety of foods eaten was suggested in the results. A commercially developed product (CM-AT by Curemark) has been specifically developed to target enzyme deficiencies that affect the availability of amino acids in children with autism; fecal chymotrypsin is used as a biomarker. Curemark (www.curemark.com) notes that it has reached its targeted enrollment for a phase III study of a total 170 children with autism at 18 sites. The unpublished Curemark study is interesting, and the FDA is reviewing its findings; but further conclusions await the published results. There are no reported trials of probiotics for ASD.

Micronutrients (Vitamins and Minerals)

Although multivitamin and mineral levels generally are not found to be abnormal in children with autism, biomarkers of general nutritional status have been reported to be associated with autism severity.⁵⁰ One open-label study of 44 individuals with autism, aged 2 to 28 years, who were selected because they (or their parents) preferred a natural treatment, reported a benefit⁵¹. There are only 2 RCT clinical trials of multivitamin/multimineral supplements for children with autism, both from the same group. The first randomized 20 children (aged 3–8 years) and reported the micronutrient supplement yielded significantly better sleep and gastrointestinal symptoms than placebo.⁵² Another RCT of an oral vitamin/mineral supplement for 3 months with 141 children and adults with ASD showed an improved nutritional and metabolic status of children with autism, including improvements in methylation, GSH, oxidative stress, sulfation, ATP, NADH, and NADPH.⁵³ The micronutrient-treated group also had significantly greater improvements on measures of global change ($P = .008$), hyperactivity ($P = .003$), and tantrums ($P = .009$).⁵³

Despite limited evidence for the efficacy of vitamin and mineral supplements for autism, there is widespread usage. The promising results from 2 RCTs suggest benefit from a safe, easy to use, and relatively inexpensive agent.

Immune Therapies

Evidence is accumulating that there are subgroups of patients with ASD that have immune deficiencies and signs of autoimmunity, such as atopy.¹⁰ Various approaches have been tried to boost immune function or block autoimmunity. One of the most

457 obvious candidates has been IVIG treatment, and there are now 6 published open-
458 label trials of IVIG treatment with ASD.

459 In one open-label study, IVIG treatment improved eye contact, speech, behavior,
460 echolalia, and other autistic features.⁵³ Others have claimed that IVIG treatment led
461 to improvements in gastrointestinal signs and symptoms as well as behavior. Subse-
462 quent studies have shown questionable benefits and mixed results for language and
463 behavior.

464 IVIG is a biomedical treatment whose overall results have been weak, and it carries
465 some significant risks. Other immune-boosting therapies may be of benefit but have
466 not been adequately studied. For future studies, it is unclear if an underlying immuno-
467 logic dysfunction is present in all individuals with ASD or if treatment trials should
468 target the patients with demonstrable inflammatory changes.

469 **Chelation**

471 Chelation, a process for removing heavy metals from the blood, has been used in
472 treating ASD based on the unproven theory that ASD is caused by heavy metal
473 toxicity; there is no convincing evidence of heavy metal toxicity from biochemical
474 studies in ASD. The hypothesized accumulation of heavy metals, particularly mercury,
475 would presumably be caused by the body's inability to clear the heavy metals, by
476 increased exposure, or both.

477 Detoxification involves several intermittent courses of oral 2, 3-dimercaptosuccinic
478 acid (DMSA) or the intravenous chelator ethylenediaminetetraacetic acid, with periodic
479 elemental analysis of urine. According to proponents, successful detoxification treat-
480 ment requires clearing the gastrointestinal tract of harmful dysbiotic flora and bolstering
481 metabolism with essential nutrients, so that the individual can tolerate detoxification.

482 Two related studies have been published^{54,55} involving 65 children with ASD who
483 received one course of DMSA for 3 days. Selected for high urinary excretion of toxic
484 metals following the DMSA administration, 49 were randomly assigned in a double-
485 blind design to receive either 6 additional rounds of DMSA or placebo. DMSA was
486 reportedly well tolerated and resulted in high excretion of heavy metals, normalization
487 of red blood cell GSH, and possibly improved ASD symptoms. Further studies are
488 needed to confirm these results.

489 Chelation is controversial because of its risks and because of its questionable
490 clinical findings, and the Institute of Medicine recently issued warnings. The most
491 common side effects are diarrhea and fatigue. Less common side effects include
492 abnormal complete blood count, liver function tests, and mineral levels. Renal and he-
493 patic toxicity is possible with oral agents, and seizures have been reported. Some pa-
494 tients may experience a sulfur smell, regression, gastrointestinal symptoms, or rash.

495 **Summary of Biomedical Treatments for Autism and Future Directions**

497 Research on CAM biomedical treatments for autism remains in its early stages, but
498 emerging data suggest several possible directions for current treatments (**Tables 1**
499 **and 2**) and future development. Melatonin for sleep induction is supported by 3 of
500 5 RCTs in children with ASD. Omega-3 fatty acids have 2 positive trending RCTs sug-
501 gesting the possibility of clinical value for treating hyperactivity associated with ASD,
502 but this might mirror recent findings of the putative efficacy of omega-3 fatty acids in
503 treating ADHD. Methylcobalamin may induce behavioral improvements, according to
504 a single RCT, but the treatment involves repeated injections several times weekly.
505 NAC has one RCT suggesting improvement in irritability. Memantine, which is an
506 established prescription drug treatment for Alzheimer disease, showed encouraging
507 results on language and socialization in one open-label series. Digestive enzyme

Table 1
Evaluations of biomedical CAM treatments for ASD: the evidence base

Treatment	Quality of Evidence	Strength of Recommendations Based on Data	Evidence Base in Youth
Melatonin	Good	Recommend strongly	18 trials, 5 RCT
Omega-3 fatty acids	Good	Recommend	4 open trials, 2 RCT
Multivitamin/ micronutrients	Fair	Recommend	2 RCTs
NAC	Fair	Neutral/recommend	1 RCT with group significance
Memantine	Fair	Neutral/recommend	3 open trials, ongoing multisite
Digestive enzymes	Poor	Neutral	Anecdotal evidence
Methylcobalamin (methyl B12)	Fair	Neutral	1 RCT w/o significance
Immune therapies intravenous	Poor	Insufficient data	None
Immunoglobulins	Poor	Insufficient data	None
Chelation	Poor	Insufficient data	None

Abbreviation: w/o, without.

supplementation is weakly supported by weak data, but a recent unpublished study suggests possible benefit. Micronutrients (multivitamin and multimineral mixtures), based on 2 RCTs, may improve tantrums, hyperactivity, sleep, and gastrointestinal symptoms. IVIGs have mixed findings in open-label trials (no controlled trials), entail medical risks, and require repeated injections. Chelation showed trends toward improvements in sociability, language, and cognition in a single RCT; but again medical risks are significant.

Taken together, none of these treatments are ready for general usage; but some families might elect to try such treatments. It is desirable for practitioners and families

Table 2
Evaluation of biomedical CAM treatments for ASD: authors' personal clinical opinion

Treatment	Strength of Recommendations Based on Published Data	Author's Clinical Recommendations
Melatonin	Reasonably good studies	Very useful
Omega-3 fatty acids	Improvement trends	Suggest always
Multivitamin/micronutrients	Possible benefit	Routinely recommend
NAC	Promising	Suggest
Memantine	Good open label	Frequently consider
Methylcobalamin (methyl B12)	Promising for subgroup	Suggest cautiously
Digestive enzymes	Not good evidence, yet	Suggest for GI symptoms
Immune therapies	No good data	Discourage
IVIG	No good evidence	Discourage
Chelation	Not good evidence	Discourage

Abbreviation: GI, gastrointestinal.

559 to work together to review, evaluate, and perhaps select the treatments that offer the
560 most promise, have a rationale for use, fit with the families' values, and have evidence
561 for safety and possible efficacy.

562 Multiple levels for intervention in the treatment of ASD are possible. Reviewing and
563 monitoring the levels for intervention assures an integrated approach to autism treat-
564 ment. A thorough medical assessment includes a review of symptoms, including a
565 possible genetic, neurologic, and gastrointestinal workup and consideration of other
566 medical symptoms when indicated. Applied behavioral analysis approaches, speech
567 and language assessment followed by therapies indicated by these evaluations, and
568 possible occupational therapy should be considered. Education, help in identifying
569 appropriate resources, and overall support is an essential part of the collaborative
570 relationship between the practitioner and the family.

571 Conventional psychopharmacology should be considered for severe symptoms
572 associated with autism, such as aggression, irritability, and anxiety. Integrated into
573 these interventions should be a thoughtful review and possible use of biomedical
574 CAM treatments, including melatonin for sleep, micronutrients, and omega-3 fatty
575 acids. Other interventions with promise and some safety data include NAC, digestive
576 enzymes, and methylcobalamin.

577 REFERENCES

- 580 1. Birdee GS, Phillips RS, Davis RB, et al. Factors associated with pediatric use of
581 complementary and alternative medicine. *Pediatrics* 2010;125(2):249–56.
- 582 2. Wong HH, Smith RG. Patterns of complementary and alternative medical
583 therapy use in children diagnosed with autism spectrum disorders. *J Autism*
584 *Dev Disord* 2006;36(7):901–9.
- 585 3. Hanson E, Kalish LA, Bunce E, et al. Use of complementary and alternative
586 medicine among children diagnosed with autism spectrum disorder. *J Autism*
587 *Dev Disord* 2007;37(4):628–36.
- 588 4. Ben-Arye E, Frenkel M, Klein A, et al. Attitudes toward integration of comple-
589 mentary and alternative medicine in primary care: perspectives of patients, phy-
590 sicians and complementary practitioners. *Patient Educ Couns* 2008;70(3):
591 395–402.
- 592 5. Hallmayer J, Cleveland S, Torres A, et al. Genetic heritability and shared environ-
593 mental factors among twin pairs with autism. *Arch Gen Psychiatry* 2011;68(11):
594 1095–102.
- 595 6. Sanders SJ, Murtha MT, Gupta AR, et al. De novo mutations revealed by whole-
596 exome sequencing are strongly associated with autism. *Nature* 2012;485(7397):
597 237–41.
- 598 7. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome in-
599 tegrates intrinsic and environmental signals. *Nat Genet* 2003;33(Suppl):245–54.
- 600 8. Saresella M, Marventano I, Guerini FR, et al. An autistic endophenotype results
601 in complex immune dysfunction in healthy siblings of autistic children. *Biol Psy-*
602 *chiatry* 2009;66(10):978–84.
- 603 9. Rutten BP, Mill J. Epigenetic mediation of environmental influences in major psy-
604 chotic disorders. *Schizophr Bull* 2009;35(6):1045–56.
- 605 10. Goines P, Van de Water J. The immune system's role in the biology of autism.
606 *Curr Opin Neurol* 2010;23(2):111–7.
- 607 11. James SJ, Melnyk S, Fuchs G, et al. Efficacy of methylcobalamin and folic acid
608 treatment on glutathione redox status in children with autism. *Am J Clin Nutr*
609 2009;89(1):425–30.

- 610 12. Frye RE, Rossignol DA. Mitochondrial dysfunction can connect the diverse med-
611 ical symptoms associated with autism spectrum disorders. *Pediatr Res* 2011;
612 69(5 Pt 2):41R–7R.
- 613 13. Bell JG, Miller D, MacDonald DJ, et al. The fatty acid compositions of erythro-
614 cyte and plasma polar lipids in children with autism, developmental delay or
615 typically developing controls and the effect of fish oil intake. *Br J Nutr* 2010;
616 103(8):1160–7.
- 617 14. Rubenstein JL. Three hypotheses for developmental defects that may underlie
618 some forms of autism spectrum disorder. *Curr Opin Neurol* 2010;23(2):118–23.
- 619 15. Harony H, Wagner S. The contribution of oxytocin and vasopressin to mamma-
620 lian social behavior: potential role in autism spectrum disorder. *Neurosignals*
621 2010;18(2):82–97.
- 622 16. Bent S, Hendren RL. Improving the prediction of response to therapy in autism.
623 *Neurotherapeutics* 2010;7(3):232–40.
- 624 17. Hendren RL, Bertoglio K, Ashwood P, et al. Mechanistic biomarkers for autism
625 treatment. *Med Hypotheses* 2009;73(6):950–4.
- 626 18. Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. *Ment*
627 *Retard Dev Disabil Res Rev* 2005;11(2):131–42.
- 628 19. Hyman SL, Levy SE. Introduction: novel therapies in developmental disabilities–
629 hope, reason, and evidence. *Ment Retard Dev Disabil Res Rev* 2005;11(2):
630 107–9.
- 631 20. Levy SE, Hyman SL. Complementary and alternative medicine treatments for chil-
632 dren with autism spectrum disorders. *Child Adolesc Psychiatr Clin N Am* 2008;
633 17(4):803–20, ix.
- 634 21. Hoffmann TJ, Kvale MN, Hesselson SE, et al. Next generation genome-wide as-
635 sociation tool: design and coverage of a high-throughput European-optimized
636 SNP array. *Genomics* 2011;98(2):79–89 PMID:21565264 PMCID: PMC23146553.
- 637 22. McPheeters ML, Warren Z, Sathe N, et al. A systematic review of medical treat-
638 ments for children with autism spectrum disorders. *Pediatrics* 2011;127(5):
639 e1312–21.
- 640 23. Narayanan A, White CA, Saklayen S, et al. Effect of propranolol on functional
641 connectivity in autism spectrum disorder—a pilot study. *Brain Imaging Behav*
642 2010;4(2):189–97.
- 643 24. King BH, Wright DM, Handen BL, et al. Double-blind, placebo-controlled study
644 of amantadine hydrochloride in the treatment of children with autistic disorder.
645 *J Am Acad Child Adolesc Psychiatry* 2001;40(6):658–65.
- 646 25. Posey DJ, Kem DL, Swiezy NB, et al. A pilot study of D-cycloserine in subjects
647 with autistic disorder. *Am J Psychiatry* 2004;161(11):2115–7.
- 648 26. Chez MG, Aimonovitch M, Buchanan T, et al. Treating autistic spectrum disorders
649 in children: utility of the cholinesterase inhibitor rivastigmine tartrate. *J Child*
650 *Neurol* 2004;19(3):165–9.
- 651 27. Deutsch SI, Urbano MR, Neumann SA, et al. Cholinergic abnormalities in autism:
652 is there a rationale for selective nicotinic agonist interventions? *Clin Neurophar-*
653 *macol* 2010;33(3):114–20.
- 654 28. Chez MG, Burton Q, Dowling T, et al. Memantine as adjunctive therapy in chil-
655 dren diagnosed with autistic spectrum disorders: an observation of initial clinical
656 response and maintenance tolerability. *J Child Neurol* 2007;22(5):574–9.
- 657 29. Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality
658 of life. *Med Hypotheses* 2009;72(3):333–7.
- 659 30. Doyle CA, McDougle CJ. Pharmacotherapy to control behavioral symptoms in
660 children with autism. *Expert Opin Pharmacother* 2012;13(11):1615–29.

- 661 31. Lofthouse N, Hendren R, Hurt E, et al. A review of complementary and alterna-
662 tive treatments for autism spectrum disorders. *Autism Res Treat* 2012;2012:
663 870391. <http://dx.doi.org/10.1155/2012/870391>.
- 664 32. Rossignol DA. Novel and emerging treatments for autism spectrum disorders: a
665 systematic review. *Ann Clin Psychiatry* 2009;21(4):213–36.
- 666 33. Miano S, Ferri R. Epidemiology and management of insomnia in children with
667 autistic spectrum disorders. *Paediatr Drugs* 2010;12(2):75–84.
- 668 34. Wirojatan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep
669 problems in children with autism, fragile X syndrome, or autism and fragile
670 X syndrome. *J Clin Sleep Med* 2009;5(2):145–50.
- 671 35. Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic
672 review and meta-analysis. *Dev Med Child Neurol* 2011;53(9):783–92.
- 673 36. Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis
674 for treatment and future research in psychiatry. *J Clin Psychiatry* 2006;67(12):
675 1954–67.
- 676 37. Bell JG, MacKinlay EE, Dick JR, et al. Essential fatty acids and phospholipase
677 A2 in autistic spectrum disorders. *Prostaglandins Leukot Essent Fatty Acids*
678 2004;71(4):201–4.
- 679 38. Meguid NA, Atta HM, Gouda AS, et al. Role of polyunsaturated fatty acids in the
680 management of Egyptian children with autism. *Clin Biochem* 2008;41(13):1044–8.
- 681 39. Vancassel S, Durand G, Barthelemy C, et al. Plasma fatty acid levels in autistic
682 children. *Prostaglandins Leukot Essent Fatty Acids* 2001;65(1):1–7.
- 683 40. Meiri G, Bichovsky Y, Belmaker RH. Omega 3 fatty acid treatment in autism.
684 *J Child Adolesc Psychopharmacol* 2009;19(4):449–51.
- 685 41. Johnson CR, Handen BL, Zlummer M, et al. Polyunsaturated fatty acid supple-
686 mentation in young children with autism. *J Dev Phys Disabil* 2010;22(1):1–10.
- 687 42. Amminger GP, Berger GE, Schafer MR, et al. Omega-3 fatty acids supplemen-
688 tation in children with autism: a double-blind randomized, placebo-controlled pi-
689 lot study. *Biol Psychiatry* 2007;61(4):551–3.
- 690 43. Bent S, Bertoglio K, Ashwood P, et al. A pilot randomized controlled trial of
691 omega-3 fatty acids for autism spectrum disorder. *J Autism Dev Disord* 2011;
692 41(5):545–54.
- 693 44. Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of
694 children with attention-deficit/hyperactivity disorder symptomatology: system-
695 atic review and meta-analysis. *J Am Acad Child Adolesc Psychiatry* 2011;
696 50(10):991–1000.
- 697 45. Gillies D, Sinn J, Lad SS, et al. Polyunsaturated fatty acids (PUFA) for attention
698 deficit hyperactivity disorder (ADHD) in children and adolescents. *Cochrane*
699 *Database Syst Rev* 2012;(7):CD007986.
- 700 46. Bertoglio K, Jill James S, Deprey L, et al. Pilot study of the effect of methyl B12
701 treatment on behavioral and biomarker measures in children with autism.
702 *J Altern Complement Med* 2010;16(5):555–60.
- 703 47. Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral
704 N-acetylcysteine in children with autism. *Biol Psychiatry* 2012;71(11):956–61
705 PMID:22342106.
- 706 48. Adams JB, Audhya T, McDonough-Means S, et al. Effect of a vitamin/mineral
707 supplement on children and adults with autism. *BMC Pediatr* 2011;11:111.
- 708 49. Munasinghe SA, Oliff C, Finn J, et al. Digestive enzyme supplementation for
709 autism spectrum disorders: a double-blind randomized controlled trial.
710 *J Autism Dev Disord* 2010;40(9):1131–8.
- 711

- 712 50. Adams JB, Audhya T, McDonough-Means S, et al. Nutritional and metabolic
713 status of children with autism vs. neurotypical children, and the association
714 with autism severity. *Nutr Metab (Lond)* 2011;8(1):34.
- 715 51. Mehl-Madrona L, Leung B, Kennedy C, et al. Micronutrients versus standard
716 medication management in autism: a naturalistic case-control study. *J Child*
717 *Adolesc Psychopharmacol* 2010;20(2):95–103.
- 718 52. Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral sup-
719 plement for children with autistic spectrum disorder. *J Altern Complement Med*
720 2004;10(6):1033–9.
- 721 53. Gupta S. Treatment of children with autism with intravenous immunoglobulin.
722 *J Child Neurol* 1999;14(3):203–5.
- 723 54. Adams JB, Baral M, Geis E, et al. Safety and efficacy of oral DMSA therapy for
724 children with autism spectrum disorders: part A—medical results. *BMC Clin Phar-*
725 *macol* 2009;9:16.
- 726 55. Adams JB, Baral M, Geis E, et al. Safety and efficacy of oral DMSA therapy for
727 children with autism spectrum disorders: part B - behavioral results. *BMC Clin*
728 *Pharmacol* 2009;9:17.
- 729